The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial
Abstract
Objective: To assess the safety and tolerability of atacicept in patients with systemic lupus erythematosus (SLE) and the biologic effect of atacicept on B lymphocyte and immunoglobulin levels. Atacicept is a TACI‐Ig fusion protein that inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation‐inducing ligand. Methods: This phase Ib, double‐blind, placebo‐controlled, dose‐escalating trial comprised 6 cohorts of patients treated with atacicept or placebo in a 3:1 ratio of active drug to placebo (n = 8 per group; n = 7 in cohort 5). Cohorts 1–4 received a single subcutaneous dose of placebo or either 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 9 mg/kg of atacicept. Cohorts 5 and 6 received weekly doses of placebo or either 1 mg/kg or 3 mg/kg of atacicept for 4 weeks. Patients were followed up for 6 weeks (cohorts 1–4) or 9 weeks (cohorts 5 and 6). Patients with mild‐to‐moderate SLE were enrolled. Results: Biologic activity of atacicept was demonstrated by dose‐dependent reductions in immunoglobulin levels and in mature and total B cell numbers. This effect was most pronounced in the repeated‐dose cohorts and was sustained throughout the followup period. There were no changes in the numbers of T cells, natural killer cells, or monocytes. Mild injection‐site reactions occurred more frequently among the atacicept group than the placebo group. There were no differences in the frequency or type of adverse events and no severe or serious adverse events in patients treated with atacicept. Conclusion: Atacicept administered subcutaneously was well tolerated and demonstrated biologic activity consistent with the proposed mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tschopp, J., & Browning, J. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1697 · Cited by 1,480
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,174
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M., Merrill, J. T., Belmont, H. M., Askanase, A. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Self-citationCheema, G. S., Roschke, V., Hilbert, D. M., & Stohl, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s · Cited by 802
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus
Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcón, G. S., Fessler, B. J., Bastian, H., Kimberly, R. P., & Zhou, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.6 · Cited by 734
TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease
Gross, J. A., Dillon, S. R., Mudri, S., Johnston, J., Littau, A., Roque, R., Rixon, M., Schou, O., Foley, K. P., Haugen, H., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00183-2 · Cited by 626
Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice
Khare, S. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050580697 · Cited by 590
An open study of B lymphocyte depletion in systemic lupus erythematosus
Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., & Isenberg, D. A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10541 · Cited by 576
Stohl, W., Metyas, S., Tan, S., Cheema, G. S., Oamar, B., Xu, D., Roschke, V., Wu, Y., Baker, K. P., & Hilbert, D. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11354 · Cited by 503
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R., & Isenberg, D. A. (2005) · Rheumatology · doi:10.1093/rheumatology/kei080 · Cited by 364
An APRIL to remember: novel TNF ligands as therapeutic targets
Dillon, S. R., Gross, J. A., Ansell, S. M., & Novak, A. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1982 · Cited by 321
Dörner, T., Kaufmann, J., Wegener, W. A., Teoh, N., Goldenberg, D. M., & Burmester, G. R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1942 · Cited by 306
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Alarcón‐Segovia, D., Tumlin, J. A., Furie, R. A., McKay, J. D., Cardiel, M. H., Strand, V., Bagin, R. G., Linnik, M. D., Hepburn, B., & LJP 394 Investigator Consortium (2003) · Arthritis & Rheumatism · doi:10.1002/art.10763 · Cited by 244
Similarities and differences between selective and nonselective BAFF blockade in murine SLE
Ramanujam, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26385 · Cited by 210
Tan, S., Xu, D., Roschke, V., Perry, J. W., Arkfeld, D. G., Ehresmann, G. R., Migone, T., Hilbert, D. M., & Stohl, W. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10860 · Cited by 206
Accurately describing changes in disease activity in Systemic Lupus Erythematosus.
Gladman, D., Urowitz, M. B., Kagal, A., & Hallett, D. C. (2000) · PubMed · Cited by 164
Stohl, W., Xu, D., Kim, K. S., Koss, M. N., Jørgensen, T. N., Deocharan, B., Metzger, T. E., Bixler, S. A., Hong, Y. S., Ambrose, C. M., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21138 · Cited by 119
Cited by
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity
Vincent, F. B., Saulep-Easton, D., Figgett, W. A., Fairfax, K. A., & Mackay, F. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.04.003 · Cited by 445
Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., Doria, A., Hammer, A. E., Kleoudis, C., Groark, J., Bass, D., Fox, N. L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40049 · Cited by 420
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Metadata
- Authors
- Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., Kalunian, K., Dhar, P., Vincent, E., Pena‐Rossi, C., & Wofsy, D.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-11-29
- Volume
- 56
- Issue
- 12
- Pages
- 4142-4150
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1968476672
- Cited by
- 294
- References
- 22
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.